Fava M
Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA.
J Clin Psychiatry. 2000;61 Suppl 11:37-41.
Weight gain during antidepressant treatment can be either a sign of improvement in patients who have weight loss as a symptom of depression or a residual symptom in patients who overeat when depressed. However, significant weight gain during the acute phase of treatment or weight gain that continues despite achieving full remission of depressive symptoms is likely to be a side effect of antidepressant treatment. Weight gain is a relatively common problem during both acute and long-term treatment with antidepressants, and it is an important contributing factor to noncompliance. This article will review the literature with regard to the relative risk for weight gain of antidepressants. It appears that tricyclic antidepressants (TCAs) and perhaps monoamine oxidase inhibitors (MAOIs) may be more likely to cause weight gain than the selective serotonin reuptake inhibitors (SSRIs) or the newer antidepressants, with the exception of mirtazapine, which may be placed between the SSRIs and the TCAs in terms of relative risk for weight gain. Paroxetine may be more likely to cause weight gain than the other SSRIs during long-term treatment, and bupropion and nefazodone may be less likely to cause weight gain than the SSRIs in the long term, although more studies are necessary to confirm these impressions.
抗抑郁治疗期间体重增加,对于那些因抑郁症状而体重减轻的患者来说,可能是病情改善的迹象;而对于那些在抑郁时暴饮暴食的患者而言,则可能是残留症状。然而,治疗急性期出现的显著体重增加,或者在抑郁症状完全缓解后体重仍持续增加,很可能是抗抑郁治疗的副作用。在抗抑郁药的急性和长期治疗过程中,体重增加都是一个相对常见的问题,并且是导致治疗依从性不佳的一个重要因素。本文将综述有关抗抑郁药导致体重增加的相对风险的文献。三环类抗抑郁药(TCAs)以及可能的单胺氧化酶抑制剂(MAOIs)似乎比选择性5-羟色胺再摄取抑制剂(SSRIs)或新型抗抑郁药更易导致体重增加,但米氮平除外,就体重增加的相对风险而言,它可能介于SSRIs和TCAs之间。在长期治疗中,帕罗西汀可能比其他SSRIs更易导致体重增加,而安非他酮和奈法唑酮长期来看可能比SSRIs导致体重增加的可能性更小,不过还需要更多研究来证实这些观点。